In atherosclerosis, targeted inhibition of LRP5 in plaque-resident macrophages alters lipid uptake and presents a novel therapeutic avenue to mitigate lesion progression while potentially preserving its systemic metabolic benefits [21]. Here, LRP5 is linked to atherosclerosis.